These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17077547)

  • 1. Novel approach to DPI carrier lactose with mechanofusion process with additives and evaluation by IGC.
    Kumon M; Suzuki M; Kusai A; Yonemochi E; Terada K
    Chem Pharm Bull (Tokyo); 2006 Nov; 54(11):1508-14. PubMed ID: 17077547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application and mechanism of inhalation profile improvement of DPI formulations by mechanofusion with magnesium stearate.
    Kumon M; Machida S; Suzuki M; Kusai A; Yonemochi E; Terada K
    Chem Pharm Bull (Tokyo); 2008 May; 56(5):617-25. PubMed ID: 18451547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing the Surface Roughness Length Scales of Lactose Carrier Particles in Dry Powder Inhalers.
    Tan BMJ; Chan LW; Heng PWS
    Mol Pharm; 2018 Apr; 15(4):1635-1642. PubMed ID: 29490144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of surface modification on surface energy of lactose and performance of dry powder inhalations].
    Jiang RG; Zhang PW; Wang LQ; Liu H; Pan WS; Wang CL
    Yao Xue Xue Bao; 2005 Apr; 40(4):373-6. PubMed ID: 16011271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving Dry Powder Inhaler Performance by Surface Roughening of Lactose Carrier Particles.
    Tan BM; Chan LW; Heng PW
    Pharm Res; 2016 Aug; 33(8):1923-35. PubMed ID: 27091033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of dispersion enhancer selection in the development of novel tratinterol hydrochloride dry powder inhalation formulations.
    Liu T; Tong S; Liao Q; Pan L; Cheng M; Rantanen J; Cun D; Yang M
    Int J Pharm; 2023 Mar; 635():122702. PubMed ID: 36773729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface Modification of lactose carrier particles using a fluid bed coater to improve fine particle fraction for dry powder inhalers.
    Gong QQ; Tay JYS; Veronica N; Xu J; Heng PWS; Zhang YP; Liew CV
    Pharm Dev Technol; 2023 Feb; 28(2):164-175. PubMed ID: 36683577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of surface energy distributions by inverse gas chromatography to understand mechanofusion processing and functionality of lactose coated with magnesium stearate.
    Das SC; Zhou Q; Morton DA; Larson I; Stewart PJ
    Eur J Pharm Sci; 2011 Jul; 43(4):325-33. PubMed ID: 21621612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.
    Jones MD; Buckton G
    Int J Pharm; 2016 Jul; 509(1-2):419-430. PubMed ID: 27265314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers.
    Jones MD; Young P; Traini D
    Adv Drug Deliv Rev; 2012 Mar; 64(3):285-93. PubMed ID: 22265843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
    Chem Pharm Bull (Tokyo); 2004 Mar; 52(3):350-3. PubMed ID: 14993760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterising surface energy of pharmaceutical powders by inverse gas chromatography at finite dilution.
    Das SC; Stewart PJ
    J Pharm Pharmacol; 2012 Sep; 64(9):1337-48. PubMed ID: 22881445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the influence of magnesium stearate content and mixing modality on the rheological properties and in vitro aerosolization of dry powder inhaler.
    Li J; Ma S; He X; Sun Y; Zhang X; Guan J; Mao S
    Int J Pharm; 2023 Jul; 642():123179. PubMed ID: 37364785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
    Iida K; Inagaki Y; Todo H; Okamoto H; Danjo K; Luenberger H
    Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):938-42. PubMed ID: 15304985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of storage humidity on the in vitro inhalation properties of salbutamol sulfate dry powder with surface covered lactose carrier.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
    Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):444-6. PubMed ID: 15056961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.